Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "specialty-pharmaceuticals"

8 News Found

CapVest to acquire majority stake in STADA
News | September 05, 2025

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth


NATCO Pharma API unit in Mekaguda receives EIR from USFDA
Drug Approval | July 24, 2025

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483


Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg
Drug Approval | August 06, 2024

Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg

The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA


PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24
News | June 03, 2024

PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24

The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore


UPS Healthcare revolutionizes prioritized shipping with UPS Premier
Supply Chain | July 16, 2022

UPS Healthcare revolutionizes prioritized shipping with UPS Premier

Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products


Prolacta Bioscience appoints David Steinberg as CFO
People | June 08, 2022

Prolacta Bioscience appoints David Steinberg as CFO

Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.